DEGARELIX STUDY GROUP TAMMELA ET AL: "904Degarelix - a phase 11 multicentre, randomized dose-escalating study testing a novel gnrh receptor blocker in prostate cancer patients", EUROPEAN UROLOGY SUPPLEMENTS, XX, XX, vol. 4, no. 3, 1 March 2005 (2005-03-01), page 228, XP005007365, ISSN: 1569-9056 (B1)

DOEHN CHRISTIAN ET AL: "Drug evaluation: Degarelix--a potential new therapy for prostate cancer", IDRUGS, CURRENT DRUGS LTD, GB, vol. 9, no. 8, 1 August 2006 (2006-08-01), pages 565-572, XP009105353, ISSN: 1369-7056 (B1)

GARNICK M ET AL: "217 Increase in the electrocardiographic QTC interval in men with prostate cancer undergoing androgen deprivation therapy: Results of three randomized controlled clinical studies", EUROPEAN UROLOGY SUPPLEMENTS, XX, XX, vol. 3, no. 2, 1 February 2004 (2004-02-01), page 57, XP027186629, ISSN: 1569-9056 [retrieved on 2004-02-01] (B1)

GITTELMAN ET AL: "MP-08.21: A multicentre, randomised one year dose-finding study of degarelix, a gonadotrophin-releasing hormone (GnRH) receptor blocker, in prostate cancer patients", UROLOGY, BELLE MEAD, NJ, US, vol. 70, no. 3, 1 September 2007 (2007-09-01), pages 83-84, XP022248654, ISSN: 0090-4295 (B1)

IVERSEN ET AL: "MP-08.18", UROLOGY, BELLE MEAD, NJ, US, vol. 68, 1 November 2006 (2006-11-01), page 102, XP005709326, ISSN: 0090-4295 (B1)

YANNUCCI J ET AL: "The Effect of Androgen Deprivation Therapy on Fasting Serum Lipid and Glucose Parameters", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 176, no. 2, 1 August 2006 (2006-08-01), pages 520-525, XP024990465, ISSN: 0022-5347, DOI: 10.1016/J.JURO.2006.03.057 [retrieved on 2006-08-01] (B1)

SORBERA L A ET AL: "Degarelix acetate. GnRH antagonist, prostate cancer therapy", DRUGS OF THE FUTURE, PROUS SCIENCE, ES, vol. 31, no. 9, 1 September 2006 (2006-09-01), pages 755-766, XP002548773, ISSN: 0377-8282, DOI: 10.1358/DOF.2006.031.09.1024366 (B1)

TSAI HENRY K ET AL: "Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.", JOURNAL OF THE NATIONAL CANCER INSTITUTE 17 OCT 2007 LNKD- PUBMED:17925537, vol. 99, no. 20, 17 October 2007 (2007-10-17), pages 1516-1524, XP002687919, ISSN: 1460-2105 (B1)

VAN POPPEL ET AL: "A ONE-YEAR, MULTICENTRE, RANDOMISED STUDY OF DEGARELIX, A GONADATROPHIN-RELEASING HORMONE (GNRH) RECEPTOR BLOCKER, IN PROSTATE CANCER PATIENTS", EUROPEAN UROLOGY SUPPLEMENTS, XX, XX, vol. 5, no. 2, 1 April 2006 (2006-04-01), page 251, XP005522890, ISSN: 1569-9056, DOI: 10.1016/S1569-9056(06)60920-2 (B1)

VAN POPPEL H ET AL: "23 LONG-TERM EVALUATION OF DEGARELIX, A GONADOTROPHIN-RELEASING HORMONE (GNRH) RECEPTOR BLOCKER, INVESTIGATED IN A MULTICENTRE RANDOMISED STUDY IN PROSTATE CANCER (CAP) PATIENTS", EUROPEAN UROLOGY SUPPLEMENTS, XX, XX, vol. 6, no. 2, 1 March 2007 (2007-03-01), page 28, XP022686644, ISSN: 1569-9056 [retrieved on 2007-03-01] (B1)

KEATING NANCY L ET AL: "Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 20 SEP 2006, vol. 24, no. 27, 20 September 2006 (2006-09-20), pages 4448-4456, XP002687918, ISSN: 1527-7755 (B1)